Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06786741 · ClinicalTrials.gov registry record · NA
Afghan Evacuee Resettlement for Stronger Communities (AER)
A NA study, sponsored by Loyola University Chicago.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT06786741: Completed NA study, sponsored by Loyola University Chicago.
NCT06786741 is a NA study that has completed, run by Loyola University Chicago. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06786741, a NA study, has completed, sponsored by Loyola University Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
Background. Under Operation Allies Welcome, approximately 88,500 Afghan evacuees have resettled in the United States (US). Evacuees face unique integration, well-being, and mental health challenges. Settlement is nationwide, including key locations of Illinois (IL) and Tennessee (TN). Study aims. In the proposed study, investigators will pilot test a 3-week culturally responsive and flexible, sprint (rapid) intervention, AER (Afghan Evacuee Resettlement) for Stronger Communities, with Afghan evacuees in IL and TN. A beta version of the first-ever AI platform, Dost, for Afghan evacuees will also be tested. Innovation. This is the first flexible and culturally responsive intervention and AI app created for Afghan evacuees to be delivered in English and Dari. Up-to-date data from evacuees over the past year inform this intervention. Methods. To pilot test the intervention, a randomized control trial (RCT) with an optional waitlist will be conducted with approx. 50-60 evacuees across IL and TN. Community liaisons from partner agencies will also be recruited for intervention delivery. Participants in the intervention group will also be able to access the AI platform. Evacuees and liaisons will be invited to provide feedback on the intervention and evacuees will be invited to provide feedback on the platform. Expected results. Investigators expect to test the central hypothesis of the study, that individuals who receive the sprint intervention and access the AI platform will have reduced stress outcomes (integration, social relationships, and mental health) compared to those who do not. Impact. Findings will build new evidence for migrants in Chicago and nationally. This project will also further interdisciplinary collaboration across Loyola University Chicago and beyond.
Primary Outcome
Reduced stress as measured by PSS-4 instrument (0=never, 1=almost never, 2=sometimes, 3=fairly often, 4=very often \*some scoring and questions were modified to make them culturally responsive.
Interventions
- OTHER Placebo Comparator
- BEHAVIORAL AER for Stronger Communities
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-09-05 |
| Est. Completion | 2024-12-19 |
| Phase | NA |
What the finished NCT06786741 record still lists
NCT06786741 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT06786741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06786741 about?
NCT06786741 is a clinical study titled "Afghan Evacuee Resettlement for Stronger Communities (AER)". Background. Under Operation Allies Welcome, approximately 88,500 Afghan evacuees have resettled in the United States (US). Evacuees face unique integration, well-being, and mental health challenges. Settlement is nationwide, including key locations of Illinois (IL) and Tennessee (TN). Study aims. I...
What is the current status of trial NCT06786741?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2024-09-05. Estimated completion is 2024-12-19.
What interventions are being tested in trial NCT06786741?
The interventions under investigation include: Placebo Comparator (OTHER), AER for Stronger Communities (BEHAVIORAL).
Who is sponsoring clinical trial NCT06786741?
This trial is sponsored by Loyola University Chicago, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06786741's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI